Collagenase clostridium histolyticum for Dupuytren's contracture

Expert Opinion on Biological Therapy

Volumn 10, Issue 9, 2010, Pages 1395-1404

  Desai, Shaunak S ^a   Hentz, Vincent R ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

Collagenase injections; Dupuytren's disease; Enzymatic fasciotomy; Hand contractures

Indexed keywords

CALCIUM; COLLAGEN TYPE 1; COLLAGEN TYPE 2; COLLAGEN TYPE 3; COLLAGEN TYPE 4; COLLAGENASE CLOSTRIDIUM HISTOLYTICUM; METALLOPROTEINASE; UNCLASSIFIED DRUG; XIAFLEX; ZINC;

ARTHRALGIA; BLEEDING; BLISTER; CATALYSIS; CHELATION; CLINICAL TRIAL; CLOSTRIDIUM HISTOLYTICUM; CONTUSION; DEGRANULATION; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DUPUYTREN CONTRACTURE; ECCHYMOSIS; EDEMA; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME INHIBITOR COMPLEX; ENZYME SUBSTRATE COMPLEX; ERYTHEMA; FOOD AND DRUG ADMINISTRATION; HEADACHE; HEMATOMA; HUMAN; INJECTION SITE PAIN; INJECTION SITE PRURITUS; JOINT SWELLING; LACERATION; LYMPH NODE PAIN; LYMPHADENOPATHY; MAST CELL; MUSCLE SPASM; NEUTROPHIL CHEMOTAXIS; PAIN; PERIPHERAL EDEMA; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN DOMAIN; REVIEW; RHINOPHARYNGITIS; SWELLING; VASCULAR FRAGILITY; WOUND HEALING;

CLOSTRIDIUM HISTOLYTICUM; DUPUYTREN CONTRACTURE; HUMANS; MICROBIAL COLLAGENASE; TREATMENT OUTCOME;

CLOSTRIDIUM HISTOLYTICUM;

EID: 77955545217     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2010.510509     Document Type: Review

References (37)

1. Ling R. The genetic factor in Dupuytrens disease. J Bone Joint Surg Br 1963;45:709-718
2. Shaw RB, Chong A, Zhang A, et al. Dupuytrens disease: history, diagnosis and treatment. Plast Reconstr Surg 2007;120:44e-54e
3. Elliot D. Pre-1900 literature on Dupuytrens disease. Hand Clin 1999;15:175-181
4. Hurst LC, Badalamente MA. Nonoperative treatment of Dupuytrens disease. Hand Clin 1999;15:97-107, vii
5. Bassot M. Traitement de la maladie de Dupuytren par exerese pharmaco-dynamique isolee ou completee par un temps plastique uniquement cutane. Lille Chirurg 1965;20:38-44
6. Hueston J. Enzymatic fasciotomy. Hand 1971;3:38-40
7. Maclennon J, Mandl I, Howes E. Bacterial digestion of collagen. J Clin Invest 1953;32:1317-1322
8. Starkweather KD, Lattuga S, Hurst LC, et al. Collagenase in the treatment of Dupuytrens disease: an in vitro study. J Hand Surg Am 1996;21:490-495
9. Hurst LC, Badalamente MA, Hentz VR, et al. Injectable collagenase clostridium histolyticum for Dupuytrens contracture. N Engl J Med 2009;361:968-979
10. van Rijssen A, Gerbrandy F, Ter Linden H, et al. A comparison of direct outcomes of percutaneous needle fasciotomy and limited fasciectomy for Dupuytrens disease: a 6-week follow-up study. J Hand Surg Am 2006;31:717-725
11. Coert J, Nerin J, Meek M. Results of partial fasciectomy for Dupuytren disease in 261 consecutive patients. Ann Plast Surg 2006;57:13-17
12. Denkler K. Dupuytrens fasciectomies in 60 consecutive digits using lidocaine and no tourniquet. Plast Reconstr Surg 2005;115:802-810
13. Foucher G, Medina J, Navarro R. Percutaneous needle aponeureotomy: complications and results. J Hand Surg Br 2003;28:427-431
14. Sennwald G. Fasciectomy for treatment of Dupuytrens disease and early complications. J Hand Surg Am 1990;15:755-761
15. Rowley D, Chesney R, Norris S. Assessment of percutaneous fasciotomy in the management of Dupuytrens contracture. J Hand Surg Br 1984;9:163-164
16. Rodrigo J, Niebauer J, Brown R. Treatment of Dupuytrens contracture: Long term results after fasciotomy and fascial excision. J Bone Joint Surg Am 1976;58:380-387
17. Armstrong J, Hurren J, Logan A. Dermofasciectomy in the management of Dupuytrens disease. J Bone Joint Surg Br 2000;82:90-94
18. Smith A. Diagnosis and indications for surgical treatment. Hand Clin 1991;7:635-642
19. Ross D. Epidemiology of Dupuytrens contracture. Hand Clin 1999;15:53-62
20. Auxilium Pharmaceuticals. Briefing Document for Collagenase Clostridium Histolyticum (AA4500) in the Treatment of Advanced Dupuytrens Disease. United States FDA Arthritis Advisory Committee Meeting. September 16, 2009; Washington, DC: FDA, 2009. Available from: http://www.fda. gov/downloads/ AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/ ArthritisDrugsAdvisoryCommittee/ UCM182015.pdf [Last accessed 21 July 2010]
21. Matsushita O, Jung C, Katayama S, et al. Gene duplication and multiplicity of collagenases in Clostridium histolyticum. J Bacteriol 1999;181:923-933
22. Van Wart H, Steinberg D. Complementary substrate specifcities of Class I and Class II collagenases from Clostridium histolyticum. Biochemistry 1985;24:6520-6526
23. Jung C, Matsushita O, Katayama S, et al. Identification of metal ligands in the Clostridia histolyticum ColH Collagenase. J Bacteriol 1999;181(9):2816-2822
24. Badalamente MA, Hurst LC. Enzyme injection as a nonoperative treatment for Dupuytrens disease. Drug Deliv 1996;3:35-40
25. Rydevik B, Ehira T, Linder L, et al. Microvascular response to locally injected collagenase. Scand J Plast Reconstr Surg 1989;23:17-21
26. Rydevik B, Brown M, Ehira T, Norborg C. Effects of collagenase on nerve tissue. An experimental study on acute and long-term effects in rabbits. Spine 1985;10:562-566
27. Badalamente MA, Hurst LC, Hentz VR. Collagen as a clinical target: nonoperative treatment of Dupuytrens disease. J Hand Surg Am 2002;27:788-798
28. Suomalainen K, Sorsa T, Golub L, et al. Specificity of the anticollagenase action of tetracyclines; relevance to their anti-inflammatory potential. Antimicrob Agents Chemother 1992;36:227-229
29. Badalamente MA, Hurst LC. Enzyme injection as nonsurgical treatment of Dupuytrens disease. J Hand Surg Am 2000;25:629-636
30. Souza Pinto J, Remacle-Volon G, Sampaio C, Damas J. Collagenase-induced oedema in the rat paw and the kinin system. E J Pharm 1995;274:101-107
31. Gelbard M, Walsh R, Kaufman J. Collagenase for Peyronies Disease. Urol Res 1982;10:135-140
32. Mandl I, editor. Collagenase comes of age. Gordon & Breach Science Publishers, New York: 1972
33. Gelbard M, James K, Riach P, Doney F. Collagenase versus placebo in the treatment of Peyronies disease: a double blind study. J Urol 1993;149:56-68
34. Gelbard M, Lindner A, Kaufman J. The use of collagenase in the treatment of Peyronies disease. J Urol 1985;134:280-283
35. Hamilton R, Mintz G, Gelbard M. Humoral immune responses in Peyronies disease patients receiving clostridial collagenase therapy. J Urol 1986;135:641-647
36. Badalamente MA, Hurst LC. Efficacy and safety of injectable mixed collagenase subtypes in the treatment of Dupuytrens contracture. J Hand Surg Am 2007;32:767-774
37. Rosebraugh CJ. BLA Approval Letter: BLA 125338/0. United States FDA correspondence to Auxiluim Pharmaceuticals. 2 February 2010. p. 13